2 June 2015 in Scientific Reports
Chronic hepatitis B virus (HBV) infection is prevalent, deadly and seldom cured due to the persistence of viral episomal DNA (cccDNA) in infected cells. Newly developed genome engineering tools may offer the ability to directly cleave viral DNA, thereby promoting viral clearance. Here, we show that the CRISPR/Cas9 system can specifically target and cleave conserved regions in the HBV genome, resulting in robust suppression of viral gene expression and replication. Upon sustained expression of Cas9 and appropriately chosen guide RNAs, we demonstrate cleavage of cccDNA by Cas9 and a dramatic reduction in both cccDNA and other parameters of viral gene expression and replication. Thus, we show that directly targeting viral episomal DNA is a novel therapeutic approach to control the virus and possibly cure patients.
4 August 2014 in Proceedings of the National Academy of Sciences
Significance: Major obstacles for using human hepatocytes to study hepatitis B virus (HBV) pathobiology are rapid loss of hepatocyte function after plating and the variability between hepatocyte donors. We show that micropatterning and coculturing of primary human hepatocytes with fibroblasts (MPCC format) maintains prolonged infection that is restricted by the innate immune response, and can be further boosted by suppression of this response. To address the problem of donor variability, we show that induced pluripotent stem cells (iPSC) differentiated into hepatocyte-like cells support HBV infection in a differentiation-dependent manner. Our study opens an avenue for using these systems to study virus–host interactions and test antiviral drugs, and suggests HBV permissiveness as a surrogate reporter to assess the degree of differentiation of candidate iPSC-derived hepatocyte-like cells.
13 December 2019 in The Journal of Immunology
Functional peptides encoded by short open reading frames are emerging as important mediators of fundamental biological processes. In this study, we identified a micropeptide produced from a putative long noncoding RNA (lncRNAs) that is important in controlling innate immunity. By studying lncRNAs in mice macrophages, we identified lncRNA 1810058I24Rik, which was downregulated in both human and murine myeloid cells exposed to LPS as well as other TLR ligands and inflammatory cytokines. Analysis of lncRNA 1810058I24Rik subcellular localization revealed that this transcript was localized in the cytosol, prompting us to evaluate its coding potential. In vitro translation with 35S-labeled methionine resulted in translation of a 47 aa micropeptide. Microscopy and subcellular fractionation studies in macrophages demonstrated endogenous expression of this peptide on the mitochondrion. We thus named this gene mitochondrial micropeptide-47 (Mm47). Crispr–Cas9–mediated deletion of Mm47, as well as small interfering RNA studies in mice primary macrophages, showed that the transcriptional response downstream of TLR4 was intact in cells lacking Mm47. In contrast, Mm47-deficient or knockdown cells were compromised for Nlrp3 inflammasome responses. Activation of Nlrc4 or Aim2 inflammasomes were intact in cells lacking Mm47. This study therefore identifies, to our knowledge, a novel mitochondrial micropeptide Mm47 that is required for the activation of the Nlrp3 inflammasome. This work further highlights the functional activity of short open reading frame–encoded peptides and underscores their importance in innate immunity.
1 August 2016 in Journal of Hepatology
1 March 2012 in Analytical Biochemistry